Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 11/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269525 | 1.00 | HSD17B1 (0.50) | HSD17B1ESR1ESR2CYP1A2DRD2 | |
| SCHEMBL21453381 | 0.92 | ESR1 (0.44) | HSD17B1ESR1ESR2CYP1A2DRD2 | |
| SCHEMBL5319753 | 0.89 | HSD17B1 (0.50) | HSD17B1ESR1ESR2CYP1A2DRD2 | |
| SCHEMBL5028772 | 0.89 | ESR1 (0.46) | HSD17B1ESR1ESR2CYP1A2CYP3A4 | |
| SCHEMBL14007352 | 0.87 | CYP1A2 (0.48) | ESR1ESR2CYP1A2DRD2DRD1 | |
| SCHEMBL25940944 | 0.86 | CYP1A2 (0.47) | ESR1ESR2CYP1A2DRD2DRD1 | |
| SCHEMBL29439100 | 0.83 | HSD17B1 (0.64) | HSD17B1ESR1ESR2DRD2DRD1 | |
| SCHEMBL788852 | 0.83 | HSD17B1 (0.64) | HSD17B1ESR1ESR2DRD2DRD1 | |
| Fluorene SCHEMBL28670106 | 0.76 | CYP1A2 (0.58) | HSD17B1ESR1ESR2CYP1A2DRD2 | |
| SCHEMBL3198655 | 0.74 | ALDH1A1 (0.41) | ESR1ESR2CYP1A2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335659-B2 | Substituted 10-aryl-11H-benzo[b]fluorenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors | N.V. ORGANON (NL) | 2008-02-26 | — | — | US | disclosed |
| EP-1272471-B1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | ORGANON NV (NL) | 2007-10-03 | — | — | EP | disclosed |
| EP-1272471-B1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | ORGANON NV (NL) | 2007-10-03 | — | — | EP | disclosed |
| EP-1478613-B1 | SUBSTITUTED 10-ARYL-11H-BENZO¬B|FLUORENES FOR SELECTIVE EFFECTS ON ESTROGEN RECEPTORS | AKZO NOBEL NV (NL) | 2006-05-24 | — | — | EP | disclosed |
| US-20050159405-A1 | Substituted 10-aryl-11h-benzo[b]fluourenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors | AKZO NOBEL, N.V. PATENT DEPARTMENT (NL) | 2005-07-21 | — | — | US | disclosed |
| US-6686371-B2 | HAVING AN 11H-BENZO(B)FLUORENE, AN 11H-INDENO-(1,2-B) QUINOLINE, A BENZ(A)ANTHRACENE OR ANALOGOUS SKELETON AND AN AFFINITY FOR THE ESTROGEN RECEPTOR; CONTRACEPTIVES; MENOPAUSAL COMPLAINTS, OSTEOPOROSIS; ANTITUMOR AGENTS | AKZO NOBEL N.V. (NL) | 2004-02-03 | — | — | US | disclosed |
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | N.V. ORGANON (NL) | 2003-07-31 | — | — | US | disclosed |
| EP-1272471-A1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | Akzo Nobel N.V. (NL) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001072713-A1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | AKZO NOBEL N.V. (NL) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159405-A1 | Substituted 10-aryl-11h-benzo[b]fluourenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors | ESR1, ESR2, ESRRA | HSD17B1 348/4885ESR1 1/4885ESR2 2/4885 |
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | ESRRA, ESRRB, ESRRG | HSD17B1 61/4885ESR1 6/4885ESR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.